Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Morphic Holding, Inc. - Common Stock (NQ:MORF)

56.99 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Morphic Holding, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors
From Robbins LLP
Via Business Wire
News headline image
Morphic to Present at November Investor Conferences
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17
Via Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5
Via Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10
Via Investor Brand Network
News headline image
NASDAQ: MORF Investor Notice: Investigation over Possible Securities Laws Violations by Morphic Holding, Inc. ↗
San Diego, CA -- (SBWIRE) -- 11/01/2023 -- Morphic Holding, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
From Johnson Fistel, LLP
Via Business Wire
News headline image
Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation
From Johnson Fistel, LLP
Via Business Wire
Morphic Holding Inc. (NASDAQ: MORF) Highlighted for Surprising Price Action
Via Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
From Morphic Therapeutic
Via GlobeNewswire
News headline image
MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic to Present at the Jefferies Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition- 
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Therapeutic Announces Proposed Public Offering
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
Call to discuss topline data from EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis 
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
From Morphic Therapeutic
Via GlobeNewswire
News headline image
Morphic to Present at SVB Leerink Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.